Biologically equivalent substitutive technology: what is needed to manufacture pluripotent stem cells for next-generation platforms for discovery and therapy

Paul A. De Sousa

doi:10.2217/rme.13.50

Biologically equivalent substitutive technology: what is needed to manufacture pluripotent stem cells for next-generation platforms for discovery and therapy

Paul A. De Sousa^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	519-521
Number of pages	3
Journal	Regenerative medicine
Volume	8
Issue number	5
DOIs	https://doi.org/10.2217/rme.13.50
Publication status	Published - Sept 2013

Keywords / Materials (for Non-textual outputs)

bioprocessing
cell culture
drug delivery
polymer substrate
small molecule
RENEWAL
FATE

Access to Document

10.2217/rme.13.50

Cite this

@article{eabc0959ea57427b97d801a787a49b3e,

title = "Biologically equivalent substitutive technology: what is needed to manufacture pluripotent stem cells for next-generation platforms for discovery and therapy",

keywords = "bioprocessing, cell culture, drug delivery, polymer substrate, small molecule, RENEWAL, FATE",

author = "\{De Sousa\}, \{Paul A.\}",

year = "2013",

month = sep,

doi = "10.2217/rme.13.50",

language = "English",

volume = "8",

pages = "519--521",

journal = "Regenerative medicine",

issn = "1746-0751",

publisher = "Taylor \& Francis",

number = "5",

}

TY - JOUR

T1 - Biologically equivalent substitutive technology: what is needed to manufacture pluripotent stem cells for next-generation platforms for discovery and therapy

AU - De Sousa, Paul A.

PY - 2013/9

Y1 - 2013/9

KW - bioprocessing

KW - cell culture

KW - drug delivery

KW - polymer substrate

KW - small molecule

KW - RENEWAL

KW - FATE

U2 - 10.2217/rme.13.50

DO - 10.2217/rme.13.50

M3 - Editorial

SN - 1746-0751

VL - 8

SP - 519

EP - 521

JO - Regenerative medicine

JF - Regenerative medicine

IS - 5

ER -